Foliglurax Failed in Trial to Ease Side Effects of Long-term Levodopa
In a final report on the Phase 2 AMBLED trial, scientists detailed the failure of Foliglurax (PTX002331) — once an investigational therapy for Parkinson’s disease — to significantly reduce some of the side effects associated with the long-term use of levodopa. “There was no evidence in this study…